Neoadjuvant Treatment of Esophageal Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2010 Aug 11

PMID 20698042

Citations 34

Authors

Nicholas P Campbell

Victoria M Villaflor

Affiliations

Soon will be listed here.

Abstract

The management of esophageal cancer has been evolving over the past 30 years. In the United States, multimodality treatment combining chemotherapy and radiotherapy (RT) prior to surgical resection has come to be accepted by many as the standard of care, although debate about its overall effect on survival still exists, and rightfully so. Despite recent improvements in detection and treatment, the overall survival of patients with esophageal cancer remains lower than most solid tumors, which highlights why further advances are so desperately needed. The aim of this article is to provide a complete review of the history of esophageal cancer treatment with the addition of chemotherapy, RT, and more recently, targeted agents to the surgical management of resectable disease.

Citing Articles

Nomogram based on multimodal magnetic resonance combined with B7-H3mRNA for preoperative lymph node prediction in esophagus cancer.

Xu Y, Lu P, Gao M, Wang R, Li Y, Guo R World J Clin Oncol. 2024; 15(3):419-433.

PMID: 38576593 PMC: 10989267. DOI: 10.5306/wjco.v15.i3.419.

Metastatic Esophageal Adenocarcinoma Presenting as Neck Dermal Metastasis.

Ibrahim-Shaikh S, Shaikh N, Daboul N, Alshaikhnassir E, Hafez M, Freiser M Case Rep Dermatol Med. 2024; 2024:7951391.

PMID: 38264294 PMC: 10805548. DOI: 10.1155/2024/7951391.

Left versus right approach for middle and lower esophageal squamous cell carcinoma: A propensity score-matched study.

Zhang X, Qi K, Huang W, Liu J, Lin G, Li J Front Oncol. 2022; 12:858660.

PMID: 36582805 PMC: 9792602. DOI: 10.3389/fonc.2022.858660.

Radiomics models based on CT at different phases predicting lymph node metastasis of esophageal squamous cell carcinoma (GASTO-1089).

Peng G, Zhan Y, Wu Y, Zeng C, Wang S, Guo L Front Oncol. 2022; 12:988859.

PMID: 36387160 PMC: 9643555. DOI: 10.3389/fonc.2022.988859.

Tumor microenvironment characterization in esophageal cancer identifies prognostic relevant immune cell subtypes and gene signatures.

Zhang Y, Zhu M, Mo J, Xian L Aging (Albany NY). 2021; 13(24):26118-26136.

PMID: 34954689 PMC: 8751614. DOI: 10.18632/aging.203800.

References

Lorenzen S, Schuster T, Porschen R, Al-Batran S, Hofheinz R, Thuss-Patience P . Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009; 20(10):1667-73. DOI: 10.1093/annonc/mdp069. View

OReilly S, Forastiere A . Is surgery necessary with multimodality treatment of oesophageal cancer. Ann Oncol. 1995; 6(6):519-21. DOI: 10.1093/oxfordjournals.annonc.a059237. View

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V . Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326(24):1593-8. DOI: 10.1056/NEJM199206113262403. View

Tew W, Kelsen D, Ilson D . Targeted therapies for esophageal cancer. Oncologist. 2005; 10(8):590-601. DOI: 10.1634/theoncologist.10-8-590. View

Nygaard K, Hagen S, Hansen H, Hatlevoll R, Hultborn R, Jakobsen A . Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992; 16(6):1104-9; discussion 1110. DOI: 10.1007/BF02067069. View

Safran H, Suntharalingam M, DiPetrillo T, Ng T, Doyle L, Krasna M . Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys. 2007; 70(2):391-5. DOI: 10.1016/j.ijrobp.2007.07.2325. View

Zambon P, Talamini R, La Vecchia C, Dal Maso L, Negri E, Tognazzo S . Smoking, type of alcoholic beverage and squamous-cell oesophageal cancer in northern Italy. Int J Cancer. 2000; 86(1):144-9. DOI: 10.1002/(sici)1097-0215(20000401)86:1<144::aid-ijc23>3.0.co;2-b. View

Gee D, Rattner D . Management of gastroesophageal tumors. Oncologist. 2007; 12(2):175-85. DOI: 10.1634/theoncologist.12-2-175. View

10.

Mariette C, Finzi L, Piessen G, Van Seuningen I, Triboulet J . Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg. 2004; 29(1):39-45. DOI: 10.1007/s00268-004-7542-x. View

11.

Wang C, Ding T, Chang L . [A randomized clinical study of preoperative chemotherapy for esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi. 2002; 23(3):254-5. View

12.

Rohatgi P, Swisher S, Correa A, Wu T, Liao Z, Komaki R . Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2005; 106(3):552-8. DOI: 10.1002/cncr.21601. View

13.

KUNATH U, Fischer P . [Radical nature and life expectancy in the surgical treatment of esophageal and cardial carcinoma]. Dtsch Med Wochenschr. 1984; 109(12):450-3. DOI: 10.1055/s-2008-1069212. View

14.

Wouters M, Wijnhoven B, Karim-Kos H, Blaauwgeers H, Stassen L, Steup W . High-volume versus low-volume for esophageal resections for cancer: the essential role of case-mix adjustments based on clinical data. Ann Surg Oncol. 2007; 15(1):80-7. PMC: 2190337. DOI: 10.1245/s10434-007-9673-4. View

15.

Xiao Z, Yang Z, Liang J, Miao Y, Wang M, Yin W . Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003; 75(2):331-6. DOI: 10.1016/s0003-4975(02)04401-6. View

16.

Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A . Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004; 53(7):925-30. PMC: 1774092. DOI: 10.1136/gut.2003.025080. View

17.

Greil R, Stein H . Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?. Lancet Oncol. 2007; 8(3):189-90. DOI: 10.1016/S1470-2045(07)70053-0. View

18.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

19.

Schlag P . Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg. 1992; 127(12):1446-50. DOI: 10.1001/archsurg.1992.01420120080015. View

20.

Urschel J, Vasan H, Blewett C . A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2002; 183(3):274-9. DOI: 10.1016/s0002-9610(02)00795-x. View